Crizotinib
- BNF:
- 8.1.5
- Status:
- Red
- Decision Date:
- October 2013
Comments
RED:
- NICE TA406: untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. (Decision date - Oct 2016).
- NICE TA422: previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. (Decision date - January 2017).
- NICE TA529: for treating ROS1-positive advanced non-small-cell lung cancer. (NHSE commissioned). (Decision date - August 2018).
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again